Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...
Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...
Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors ditch one-size-fits-all treatments ...
Investor's Business Daily on MSN
Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.
Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback